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Abstract: Ultrasound (US) sonication with microbubbles (MBs) has the potential to disrupt 
blood vessels and enhance the delivery of drugs into the sonicated tissues. In this study, mouse 
ear tumors were employed to investigate the therapeutic effects of US, MBs, and pegylated 
  liposomal doxorubicin (PLD) on tumors. Tumors started to receive treatments when they grew up 
to about 15 mm3 (early stage) with injection of PLD 10 mg/kg, or up to 50 mm3 (medium stage) 
with PLD 6 (or 4) mg/kg. Experiments included the control, PLD alone, PLD + MBs + US, US 
alone, and MBs + US groups. The procedure for the PLD + MBs + US group was that PLD was 
injected first, MB (SonoVue) injection followed, and then US was immediately sonicated on the 
tumor. The results showed that: (1) US sonication with MBs was always able to produce a further 
hindrance to tumor growth for both early and medium-stage tumors; (2) for the medium-stage 
tumors, 6 mg/kg PLD alone was able to inhibit their growth, while it did not work for 4 mg/kg 
PLD alone; (3) with the application of MBs + US, 4 mg/kg PLD was able to inhibit the growth of 
medium-stage tumors; (4) for early stage tumors after the first treatment with a high dose of PLD 
alone (10 mg/kg), the tumor size still increased for several days and then decreased (a biphasic 
pattern); (5) MBs + US alone was able to hinder the growth of early stage tumors, but unable to 
hinder that of medium stage tumors. The results of histological examinations and blood perfusion 
measurements indicated that the application of MBs + US disrupts the tumor blood vessels and 
enhances the delivery of PLD into tumors to significantly inhibit tumor growth.
Keywords: ultrasound, microbubbles, nanodrug, mouse tumor, vascular disruption, tumor 
growth response
Introduction
The aim of chemotherapy is to deliver anticancer drug(s) to the targeted tumors with 
sufficiently high doses and to produce minimum side effects on normal tissue.1 Drug 
delivery with nanotechnology can result in preferential transport of drugs to tumors, 
owing to the enhanced permeability and retention effect.2 Vasculature plays a crucial role 
in tumor growth, metastasis, and drug delivery. The therapeutic strategy of nanodrugs 
is based on tumor microenvironment and on morphological and functional character-
istics of tumor vasculature.3,4 Tumors commonly secrete vascular endothelial growth 
factor, and their vessels usually have wider intercellular junctions than normal vessels 
do, and many tumor vessels have fenestrated structures.5–7 The abnormal organization 
and structure of the tumor vasculature results in tortuous and leaky vessels and rather 
heterogeneous blood flow.8 Tumor vessels with different morphological characteristics 
coexist in the same tumor, and a previous study9 showed that the process of tumor 
growth from initiation to necrosis could be classified into four characteristic stages and 
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that tumor vascular morphology drastically changed accord-
ing to tumor growth.
An effective drug accumulation in tumors can lead to 
a   significant therapeutic response for the outcome of treat-
ment.10,11 Strategies that can further increase drug   availability 
and therapeutic responses in tumor inhibition are needed. 
Ultrasound (US) sonication with microbubbles (MBs) could 
noninvasively enhance the transport of therapeutic agents to 
targeted tissues.12,13 With US sonication right after an injection 
of MBs, the MBs in the vasculature within the acoustic beam 
are interacting with the ultrasound waves. The interaction of 
ultrasound waves with MBs may cause oscillation and cavita-
tion of the bubbles and lead to the rupture of vascular walls.14–16 
For overcoming the difficulties of drug delivery posed by 
vascular walls, US sonication in the presence of MBs can 
produce ruptured openings to increase vascular permeability 
of sonicated tissues and permit a specific and effective cellular 
uptake.17–20 Studies have recently demonstrated that ultrasound-
mediated chemotherapeutics with MBs showed promising 
potential for animal tumor treatment.19,20 The therapeutic drug 
concentration increased specifically in the sonicated region and 
significantly suppressed the tumor growth.
Pegylated liposomal doxorubicin (PLD) is able to avoid 
the recognition of the reticuloendothelial system and pos-
sesses long-circulating properties to improve the delivery 
of free drug.21–23 The average size of PLD is approximately 
100 nm, which is small enough for the PLD to extravasate 
through the leaky vasculature to achieve passive accumula-
tion in tumor tissues. Previously, we have shown that focused 
US (FUS) sonication with MBs can significantly enhance the 
delivery of nanoparticles into tumor tissues.15,16 The results 
indicated that an injection of MBs followed by pulsed-FUS 
sonication is promising for nanodrug delivery in the sonicated 
tumor tissues. There have been no reports relating to the 
influence of the changes of vascular permeability through 
ruptured openings on the tumor treatment at different tumor 
growth stages. In the present study, we employ a mouse-ear 
tumor model to investigate the influences of US sonication 
in the presence of MBs on the therapeutic responses of early 
and medium-stage tumors. Different PLD dosages were also 
considered, and histological examination and blood perfusion 
measurement were used to study the tumors’ physiological 
changes due to US sonication with MBs.
Materials and methods
Reagents
The PLD (Doxil) was obtained from Alza (Bedford, MA). 
The US contrast agent (UCA) (SonoVue) used as MBs 
was purchased from Bracco (Amsterdam, Netherlands). 
Other chemicals, if not specified, were reagent grade from 
Aldrich-Sigma (St, Louis, MO).
Cell culture and animal model
Mouse colorectal adenocarcinoma CT-26 cells were received 
from American Type Culture Collection (ATCC, MD). The 
CT-26 cells were cultured in the Roswell Park Memorial 
Institute medium supplemented with 10% fetal bovine serum 
in a 37°C, 5% CO2 incubator for 24 hours with complete cell 
attachment. Cell number and viability were counted by using 
a hemocytometer with trypan blue exclusion test.
Male, 6-week-old BALB/c mice weighing 20–25 g were 
used in this study. To produce ear tumors for experiments, 
CT-26 cells (106 cells/50 µL) were inoculated subcutaneously 
into both sides of the mouse ears. Before the experiments, tumor 
size was selected according to tumor volume (TV) by the mea-
surement of length (L), width (W), and height (H) with a caliper 
and using the formula TV LW H =× × π/6 .24 All tumors 
were measured three times per week. Seven or 10 days after 
tumor cell inoculation, mice bearing tumors with an initial size 
of about 15 mm3 (early stage) or 50 mm3 (medium stage) were 
selected for the experiments. The mice were anesthetized with 
a combined solution of ketamine (30 mg/kg) and acepromaz-
ine (0.75 mg/kg) by intraperitoneal injection. The experiment 
procedure met the criteria outlined by the Institution of Animal 
Care and Use Committee of National Taiwan University, and 
the mice were handled according to the guidelines in The 
Handbook of Laboratory Animal Center, National Taiwan 
University. All experiments were designed to minimize the 
animals’ suffering.
Ultrasound sonication system
The sonication was conducted either with a 1.0-MHz US 
transducer (Sonitron 2000; Rich Mar, Inola, OK; output 
power intensity 2 W/cm2, duty cycle 50%, pulse length 
10 ms, pulse-repetition frequency 50 Hz, and sonication 
duration 60 seconds) for early stage tumors or with a 1.0-
MHz FUS transducer (A392S; Panametrics, Waltham, MA; 
diameter 38 mm, curvature radius 63.5 mm) for medium-
stage tumors, which was driven by a power amplifier 
(150A250A; Amplifier Research, Souderton, PA) connected 
to both a function generator (33220A; Agilent, Palo Alto, 
CA) and a power meter/sensor module (4421; Bird, Cleve-
land, OH). A removable cone (inner diameters for top and 
bottom 12 and 38 mm, respectively; cone length 58 mm) 
filled with distilled and degassed water was mounted on 
the bottom of the FUS transducer. The tip of the cone was 
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firmly covered with a polyurethane membrane to ensure no 
air bubbles in the water, and the cone was used to guide the 
acoustic beam to the tumor region. The center of the focal 
zone was about 5.3 mm away from the cone tip. The acoustic 
pressure at the focal point was 0.6 MPa, measured by 
a needle hydrophone (HPM1/1; Precision Acoustics, 
Dorchester, UK), and the parameters of FUS sonication used 
were 60-second sonication duration, a 10-ms pulse length, 
a 50% duty cycle, and a 50-Hz pulse-repetition frequency. 
A 3-mm-thick acoustic transmission gel (Pharmaceutical 
Innovations, Newark, NJ) was mantled to the skin over each 
tumor, and then the cone tip was immersed in the gel and 
targeted on the tumor. The cone with US transducer was 
then circularly scanned above the tumor and sonicated, as 
shown in Figure 1.
Experimental designs
We conducted the experiments to investigate the influence of 
US sonication with MBs on the tumor growth in mouse-ear 
tumors treated with anticancer nanodrug. In this study, a US 
contrast agent (SonoVue; phospholipid-coated MBs mean 
diameter 2.5 µm and concentration 2–5 × 108 bubbles/mL) 
was used as MBs. If not specified, the injected dose of MBs 
was 100 µL/kg.
growth response for early stage tumors treated 
with 10 mg/kg of PLD
To study the effect of US sonication with MBs on the thera-
peutic response of early stage tumors, we selected a small 
US probe (3 mm diameter at the tip) and an initial size of 
treated tumors of about 15 mm3 (7 days after inoculation). 
Experimental groups included the control (n = 3), PLD (PLD 
injection only, n = 6), PLD + MBs + US (PLD injection, 
followed by MBs injection and then US sonication, n = 6), US 
(US sonication only, n = 3), and MBs + US (MBs injection, 
followed by US sonication, n = 3). We injected 10 mg/kg of 
PLD into the tail veins of the tumor-bearing mice for both 
PLD and PLD + MBs + US groups, and the other two groups 
were treated with either MBs + US or US alone, respectively, 
on days 7, 14, and 21 after tumor inoculation.
growth response for medium-stage tumors treated 
with 6 mg/kg of PLD
To study the effect of US sonication with MBs on the 
therapeutic response of medium-stage tumors, we used 
an FUS transducer and an initial size of treated tumor of 
about 50 mm3 (10 days after inoculation). The mice were 
divided into five groups: the control (n = 6), PLD (n = 5), the 
PLD + MBs + US (n = 5), US (n = 3), and MBs + US (n = 3). 
Ear tumor
Ear Skin
US
beam
Scanning diameter
Ultrasound
transducer Ultrasound
driving system
Intravenous injection
Tumor
Transmission
gel
Figure 1 Experimental arrangement. The acoustic beam from the ultrasound transducer to sonicate mouse ear tumors was guided by a cone filled with degassed water. 
A 3-mm-thick ultrasound transmission gel was mantled over the ear skin and the acoustic beam was targeted on the tumor. The ultrasound beam was circularly scanned 
during sonication.
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Treatments were executed with an injection of 6 mg/kg PLD 
for both the PLD and PLD + MBs + US groups, and the other 
two groups were treated with either MBs + US or US alone, 
respectively, on days 10 and 17 after tumor inoculation.
growth response for medium-stage tumors treated 
with 4 mg/kg of PLD
To further investigate the effect of MBs + US on the thera-
peutic response, a lower dose (4 mg/kg) of PLD was used 
to treat tumors with an initial size of about 50 mm3 for both 
the PLD and PLD + MBs + US groups. The treatments were 
executed on days 10 and 17 after tumor inoculation.
Measurements of tumor blood perfusion 
with a Laser Doppler
Red blood cell perfusion was measured using a laser Doppler 
(OxyLab LDF; Oxford Optronics, Oxford, UK). The mice 
bearing ear tumors were divided into three groups: the control 
group (n = 3), the PLD group (n = 3), and the PLD + MBs + US 
group (n = 5). Blood perfusion of the ear tumors was assessed 
just before both the first treatment (on day 10 after tumor 
  inoculation) and the second treatment (on day 17). For each 
tumor, red blood cell perfusion was obtained from one 
central and two peripheral locations of the tumor using the 
Miniature Surface Probe (MSP310XP [diameter 1 mm]; AD 
  Instruments, Bella Vista, NSW, Australia) with a self-adhesive 
disc.   Estimates of perfusion were obtained at a frequency of 
5 Hz over a period of 60 seconds. The measurements for each 
sample were repeated three times, and the mean value in blood 
perfusion units was calculated. The data were expressed as 
relative blood perfusion units with percentage values.
Microscopic system and histological 
morphology
Tumor development on both ears was observed every day 
after tumor inoculation, and the mice were anesthetized 
and photomicrographed every other day for both ears under 
transillumination using a Leica MZ16FA stereomicroscope 
(Leica Microsystems, Wetzlar, Germany).
The mice were killed at the end of the experiment, and 
were then infused with 0.9% saline via the left ventricle. After 
infusion, tumor tissues were harvested from both ears, and 
the tissues were immediately frozen in liquid nitrogen and 
kept at −80°C for later histological staining.
Mouse tumor tissues were moved from the −80°C freezer 
to a −20°C Leica CM3050 S Cryostat (Meyer, TX) and 
sectioned. The tissues were embedded into a Tissue-Tek 
OCT compound (Sakura Finetek, Torrance, CA) and were 
sectioned into 5-µm-thick slices on SuperFrost glass slides 
(Thermo Fisher Scientific, Braunschweig, Germany). Tissue 
slices were stained with hematoxylin and eosin (H&E) for 
histological analysis and evaluated using a Leica DMIRB 
microscope (Leica Microsystems) with image acquisition 
software to examine the slices of H&E staining.
Statistical analysis
Statistical analysis of variance was used to evaluate the data, 
and a nonparametric Mann–Whitney U test was used to deter-
mine the level of significance of differences in sample means 
with the Statistical Package for the Social Sciences version 
16.0 software (SPSS, Chicago, IL). Values of P , 0.05 and 
P , 0.01 were considered significant.
Results
Influence of US sonication with MBs  
on tumor growth for early stage tumors 
treated with anticancer nanodrug
To investigate the therapeutic effects of US sonication with 
MBs on early stage tumors treated with anticancer nanodrug, 
we injected 10 mg/kg of PLD through the tail vein of the mice 
with an initial size of treated ear tumor of about 15 mm3 for 
both PLD and PLD + MBs + US groups, whereas the other two 
groups received US sonication with or without MBs injection. 
Figure 2 shows the tumor growth response during a sequence 
of treatments on days 7, 14, and 21 after tumor inoculation. The 
results show that the tumor growth is significantly inhibited in 
the PLD, PLD + MBs + US, and MBs + US groups, as com-
pared with the control group (P , 0.05, P , 0.01). The results 
display that US sonication with MBs after an injection of 
10 mg/kg PLD can further and earlier inhibit the tumor growth, 
as compared with PLD alone. It is also worth noting that tumor 
growth appears biphasic: the size increases after the first treat-
ment and then decreases, for both PLD and PLD + MBs + US 
groups. Meanwhile, tumor growth for the MBs + US group 
was hindered, even though there was no PLD injection.
Influences of FUS sonication with MBs 
on tumor growth and blood perfusion 
for medium-stage tumors treated with 
anticancer nanodrug
To investigate the therapeutic effects of FUS sonication 
with MBs on medium-stage tumors treated with anticancer 
nanodrug, we injected 6 mg/kg of PLD into the mice with an 
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Figure 2 Effects of ultrasound (US) sonication with microbubbles (MBs) on tumor growth for early stage tumors treated with 10 mg/kg of anticancer nanodrug. The arrows 
indicate the schedule for treatments. The figure shows the tumor growth responses for an initial size of treated tumors of about 15 mm3 with different conditions: control, 
PLD alone, PLD + MBs + US, US alone, and MBs + US.
Notes: *P , 0.05; **P , 0.01 (Mann–Whitney U test); for each group, mean ± standard deviation.
Abbreviations: US, ultrasound; MBs, microbubbles; PLD, pegylated liposomal doxorubicin.
initial size of treated ear tumor of about 50 mm3 for both PLD 
and PLD + MBs + US groups, whereas the other two groups 
received FUS sonication with or without MBs injection. 
Figure 3A shows the tumor growth responses for   treatments 
on days 10 and 17 after tumor inoculation. This figure 
  displays that the tumor growth was effectively inhibited after 
the first treatment for the PLD group (P , 0.05, as compared 
with the control group), and the tumor growth was further 
inhibited by FUS sonication with MBs (P , 0.01 between 
the PLD + MBs + US and control groups). Meanwhile, there 
was no significant difference among the control, US, and 
MBs + US groups.
Photomicrograph was used to examine the tumor growth 
for the control, PLD, and PLD + MBs + US groups on days 
10, 16, and 26 after tumor inoculation. Figure 3B, photomi-
crograph observation for the tumors, shows that the inhibition 
of tumor growth was more effective in the PLD + MBs + US 
group than the PLD group, and the tumor almost disappeared 
for the former.
Laser Doppler was used to examine the response of 
microvascular blood perfusion for the tumors after   treatment. 
We measured the tumor blood perfusion for the control, 
PLD, and PLD + MBs + US groups just before both the 
first treatment (day 10 after tumor inoculation) and the 
second treatment (day 17 after inoculation). Figure 3C 
shows that blood perfusion significantly decreased 7 days 
after the first treatment for the PLD group (P , 0.05), and 
it was further decreased by FUS sonication with MBs (the 
PLD + MBs + US group) (P , 0.01).
Histological examinations for the 
influence of FUS sonication with  
MBs on tumor tissues
Staining with H&E was used to examine the change of histol-
ogy induced in tumor tissues for the PLD, PLD + MBs + US, 
and MBs + US groups. The H&E staining of tumor tissues 
for these three groups is shown in Figure 4, depicting the 
treatment results of Figure 3. Hemorrhagic damage occurred 
rarely in the PLD and MBs + US groups, whereas for the 
PLD + MBs + US group, FUS sonication with MBs resulted 
in local suppression of neutrophil influx, interstitial edema, 
congestion, and disruption of tissue architecture.
Influence of FUS sonication with MBs on 
tumor growth for medium-stage tumors 
with a low dose of anticancer nanodrug
To further study the effect of FUS sonication with MBs 
on the therapeutic response of anticancer nanodrug for 
medium-stage tumors, we injected a low dose (4 mg/kg) 
of PLD into the mice with an initial treated tumor of size 
about 50 mm3 for both PLD and PLD + MBs + US groups. 
Figure 5 shows the tumor growth response with treatments 
on days 10 and 17 after inoculation. The results show that the 
tumor growth was significantly different between the PLD 
and PLD + MBs + US groups. There was no hindrance to 
the tumor growth for the PLD group, while the application 
of FUS sonication with MBs after the injection of PLD was 
able to significantly inhibit tumor growth.
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Figure 3 Effects of focused US sonication with MBs on tumor growth for medium-stage tumors treated with 6 mg/kg. (A) Tumor growth responses for an initial size of 
treated tumors of about 50 mm3 with different conditions: control, PLD alone, PLD + MBs + US, US alone, and MBs + US. The arrows indicate the schedule for treatments. 
(B) Photomicrographs of mouse-ear tumors (control, PLD alone, and PLD + MBs + US) on days 10, 16, and 26 after tumor inoculation (magnification: 10×). (C) Blood 
perfusion measurements of tumors before treatment on days 10 and 17, for the control, PLD, and PLD + MBs + US groups.
Notes: Mean ± SD; *P , 0.05, **P , 0.01 (Mann–Whitney U test).
Abbreviations: US, ultrasound; MBs, microbubbles; PLD, pegylated liposomal doxorubicin.
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Discussion
In this study, we investigated the synergistic effect of US 
sonication with MBs on early and medium staged tumors 
located on mouse ears treated with anticancer nanodrug. 
The results showed that: (1) US sonication in the presence 
of MBs was always able to produce a further hindrance to 
tumor growth for both early and medium-stage tumors; 
(2) the dosage of anticancer nanodrug was one of the criti-
cal factors for the tumor growth inhibition: administration 
of 6 mg/kg PLD alone was able to inhibit the growth of 
medium-stage tumors, while this did not occur for injection 
of 4 mg/kg PLD alone; (3) with the application of MBs + US 
after nanodrug administration, a low dose of PLD (4 mg/
kg) was able to inhibit the growth of medium-stage tumors;   
(4) for early stage tumors after the first treatment with a high 
dose of nanodrug alone (PLD 10 mg/kg), the tumor size still 
increased for several days and then decreased (biphasic pat-
tern); (5) the use of MBs + US alone was able to hinder the 
tumor growth of early stage tumors, but for medium-stage 
tumors MBs + US alone could not inhibit tumor growth, and 
an injection of PLD was required for effective hindrance. 
The experimental results indicated that the use of MBs + US 
can significantly affect the growth response of early stage 
tumors (Figure 2) and the application of MBs + US after 
PLD administration can enhance the anticancer treatment 
of PLD to further inhibit tumor growth for both early and 
medium-stage tumors (Figures 2, 3, and 5).
When US sonicates in the tumors right after an injection 
of MBs, the interaction of the US beam with MBs in blood 
vessels results in the bubbles’ oscillation, collapse, and even 
violent cavitation. These phenomena of MBs may disrupt 
blood vessel walls and produce vascular pores or even 
vascular rupture, which may be able to hinder the growth 
of early stage tumors (Figure 2) and improve the transport 
of nanodrug into tumor tissues to further inhibit tumor 
growth when PLD is injected before the use of US + MBs 
for both early and medium-stage tumors (Figures 2, 3, 
and 5). Meanwhile, the temperature rise in the sonicated 
tumor tissue during US sonication in the presence of MBs 
may have some thermal effects on the tumor to increase 
the blood flow for raising the delivery of nanodrug into 
tumor tissues.
MBs + US 
100×
200×
400×
20×
PLDP LD + MBs + US
Figure 4 H&E staining of tissue sections for the ear tumors after a sequence of treatments with MBs + US, PLD alone, and PLD + MBs + US.
Notes: Magnifications 20×, 100×, 200×, and 400× (yellow square).
Abbreviations: H&E, hematoxylin and eosin; MBs, microbubbles; US, ultrasound; PLD, pegylated liposomal doxorubicin.
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Figure 5 Tumor growth response of medium-staged tumors treated with 4 mg/kg of PLD with and without MBs + FUS. The arrows indicate the schedule for treatments.
Notes: Mean ± SD; *P , 0.05 (Mann–Whitney U test).
Abbreviations: PLD, pegylated liposomal doxorubicin; MBs, microbubbles; FUS, focused ultrasound.
The vascular transport of anticancer nanodrug into tumor 
tissues is related to both the stage of tumor growth9,25 and 
the use of MBs + US. For early stage tumors, the response 
of tumor growth displays a biphasic pattern (tumor size 
increases for several days and then decreases) after the first 
treatment with a high dose of PLD (10 mg/kg) alone. For 
early stage tumors, their vascular integrity is still rather intact 
for PLD and hence it impedes the transport of nanodrug into 
the tumor tissue,21,25 while the vascular permeability for PLD 
increases as the tumor enters the medium stage. This may 
be able to explain the phenomenon that early stage tumors 
still grew for several days after injection of a high dose of 
PLD (10 mg/kg), while medium-stage tumors were inhibited 
after a 6 mg/kg dose of PLD. It is also worth noting that the 
growth of early stage tumors after the first treatment was 
significantly hindered for the MBs + US group (Figure 2). 
This indicates that the bubbles’ oscillation, collapse, and 
violent cavitation in microvessels during US sonication 
disrupt microvessels sufficiently to affect the growth of early 
stage tumors. Previous studies displayed that early stage 
tumors have a much higher microvascular density,9,25 and a 
prominent antivascular effect on tumors was produced after 
US sonication with MBs.26,27 Histology demonstrated 
  disruption of vascular walls and tumor cell death in areas of 
vascular congestion and thrombosis.28 For early stage tumors, 
their microvasculature is denser but fragile, and hence more 
thorough damage may appear to suppress tumor growth after 
US sonication with MBs. The damage level of blood vessels 
to hinder tumor growth due to US sonication depends on 
tumor growth stage, quantity of injected MBs, and sonica-
tion conditions, which may be able to explain the hindrance 
difference between early and medium-stage tumors for the 
MBs + US groups in Figures 2 and 3.
The transport of nanodrug and its concentration distribu-
tion in tumor tissues are related to (1) convection, in which 
fluid flows through the vascular walls into tumor tissues and 
from tumor tissues to the adjacent normal tissues, (2) dif-
fusion, which is determined by concentration difference of 
nanodrug between intravascular and extravascular regions, 
and (3) injected dosage of nanodrug. Hence, vascular density, 
vascular permeability, and interstitial diffusivity of PLD nan-
odrug, interstitial pressure in tumors, and injected dosage are 
crucial factors affecting the anticancer treatment. Early stage 
tumors possess high vascular density, but with relatively 
intact vascular walls hampering the transport of PLD into 
tumor tissues. Hence the use of MBs + US to disrupt vascular 
integrity can effectively induce the transport of nanodrug into 
interstitial tumor tissues to hinder tumor growth. This may be 
able to explain the reason for the hindrance to tumor growth 
for the PLD + MBs + US group (P , 0.01 compared with the 
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control group) appearing significantly earlier than the PLD 
group, as shown in Figure 2. For medium-stage tumors (about 
50 mm3), they have already developed pores on vascular 
walls sufficiently large for the transport of PLD nanodrug 
to the extravascular region, while their vascular density is 
relatively less. It means that there is a longer distance for drug 
to travel to reach a therapeutic level in some tumor region. 
An administration of 6 mg/kg PLD is able to inhibit tumor 
growth, while an injection of 4 mg/kg PLD cannot result in a 
sufficiently high dose of drug in some tumor regions, due to 
the long-distance transport of drug, to hinder medium-stage 
tumor growth. FUS sonication with MBs is able to disrupt 
blood vessels to enable greater transport of PLD (Figure 4), 
making it possible to inhibit tumor growth with a dose as 
low as 4 mg/kg (Figure 5). This suggests that the use of 
MBs + US may reduce the dosage of PLD down to 4 mg/kg, 
which may avoid toxicities while maintaining antitumor 
efficacy. In addition to vascular density and permeability, 
other tumor microenvironment conditions also need to be 
considered, such as high interstitial fluid pressure, hypoxia, 
and low pH, which may hinder drug delivery and treatment 
effectiveness for a low dose of PLD to inhibit the growth of 
medium-stage tumors.
Tumor perfusion measured by laser Doppler showed that 
the reduction of blood perfusion was statistically significant 
for both the PLD and PLD + MBs + US groups (P , 0.05, 
P , 0.01) after one treatment, as shown in Figure 3C. As 
compared with Figure 3A, the tumor growth was significantly 
inhibited for the PLD group, and the tumors even shrank 
  significantly for the PLD + MBs + US group. This suggests 
that vasculature was effectively damaged by PLD treatment 
and further damaged with the application of MBs + US, while 
the reduction of blood perfusion in the control group can 
be regarded as due to the significant growth of tumor size. 
During US sonication in the presence of MBs, the oscilla-
tion, collapse, and cavitation of MBs in the acoustic beam 
produced vascular pores and disruption of vessel wall to 
increase vascular permeability significantly in the sonicated 
areas. This may have further led to the formation of smaller 
bubbles, which interacted with the US beam and caused the 
cellular bioeffects. The predominant acute effects of US 
sonication might have induced dilation of tumor vessels and 
hemorrhage, so that there would not have been the normal 
structural support for the capillaries. As the vessel wall was 
no longer functioning well, it was incapable of counteracting 
the intravascular pressure, and then the capillaries dilated 
and became leaky, even cascading to edema. Figure 4 shows 
the histological results, in which the peritumor edema was a 
characteristic finding in the tumor morphology. This implies 
that the mild intercellular fluid across the entire tumor with 
nanodrug solution might further induce tumor damage for the 
PLD + MBs + US group, while MBs + US alone enhanced the 
flow perfusion without cellular damage. Therefore, nanodrug 
delivery enhancement with MBs + US was correlated with 
structural changes created in the tissue.
In this study, a significant hindrance to tumor growth was 
achieved using MBs + US to disrupt tumor blood vessels, 
while targeted delivery of nanodrug into tumor tissue was 
enhanced. However, the associated toxicities may appear in 
other tissue when the high-pressure region of the US beam is 
scanned through those tissues, and it is likely to cause some 
vascular damage and chemotherapeutic effects on sonicated 
nontumor tissue. Furthermore, the disruption of blood vessels 
in the sonicated tumor can enhance the delivery of nanodrug 
into tumor tissues, while it may have a double-edged-sword 
effect in facilitating the intravasation of tumor cells into 
circulation to increase metastasis. In future studies, it will be 
valuable to investigate the possibility of metastasis increase 
for the PLD + MBs + US group.
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